ライフサイエンスコーパス: Hippo pathway

1 and signaling pathways of the cell (e.g. the Hippo pathway).

2 omponents of caveolae and the outputs of the Hippo pathway.

3 presses cancer cell growth by activating the Hippo pathway.

4 genesis and are negatively controlled by the Hippo pathway.

5 y independent of Lats, the key kinase of the Hippo pathway.

6 ression of Yap and Taz, the mediators of the Hippo pathway.

7 oncogene in GBM, which regulates the PTPN14/Hippo pathway.

8 r accumulation of YAP, a key mediator of the Hippo pathway.

9 size independently of proliferation and the Hippo pathway.

10 bryonic and MaSC signatures and activate the Hippo pathway.

11 factors are the most distal effectors of the Hippo pathway.

12 olved in tumorigenesis and regulation of the Hippo pathway.

13 LIM proteins are negative regulators of the Hippo pathway.

14 stions in the regulation and function of the Hippo pathway.

15 inant to other signals known to modulate the Hippo pathway.

16 ion suggests TAZ to be a redox sensor of the Hippo pathway.

17 , a highly conserved scaffold protein of the Hippo pathway.

18 cumulation of YAP/TAZ, core effectors of the Hippo pathway.

19 g a "WW-PY" binding specificity issue in the Hippo pathway.

20 ) to drive tumor growth via inactivating the Hippo pathway.

21 pneumophila to take control of the host cell Hippo pathway.

22 embrane domains in cellular feedback via the Hippo pathway.

23 present the main downstream effectors of the Hippo pathway.

24 involving hyperthermia and targeting of the Hippo pathway.

25 ight into cross-talk between the insulin and Hippo pathways.

26 utics targeting the Notch, WNT, Hedgehog and Hippo pathways.

27 imultaneous deregulation of both the Ras and Hippo pathways.

28 The Hippo pathway, a conserved kinase cascade, inhibits card

29 The Hippo pathway, a kinase cascade that prevents adult card

30 mor suppressor (Lats1/2) core kinases of the Hippo pathway, a signaling pathway that plays important

31 Here, we report that the Hippo pathway, a well-known regulator of proliferation,

32 nd RNA-seq data for master regulators of the Hippo pathway across normal human tissues identified pro

33 her, our findings elucidate the mechanism of Hippo pathway activation by Merlin and Kibra, identify a

34 e evidence that YAP activity is repressed by Hippo pathway activation upon hepatocytic maturation in

35 the regulatory protein Mob1, consistent with Hippo pathway activation.

36 ition signal, such as glucose, regulates the Hippo pathway activation.

37 mbrane recruitment and subsequent downstream Hippo pathway activation.

38 Finally, we provide evidence that the Hippo pathway activity discriminates quiescent from non-

39 insulator protein BEAF-32 as a regulator of Hippo pathway activity in Drosophila photoreceptor diffe

40 y identifies a context-specific regulator of Hippo pathway activity in post-mitotic neuronal fate, an

41 large protocadherin Fat functions to promote Hippo pathway activity in restricting tissue growth.

42 Whether and how Hippo pathway activity is limited to sustain or initiate

43 The Hippo pathway activity is modulated via inter-cellular t

44 xpanded turnover ensures a tight coupling of Hippo pathway activity to epithelial architecture.

45 SARAH domain-mediated interactions influence Hippo pathway activity.

46 ressor, and loss of NF2 severely compromises Hippo pathway activity.

47 Overall, we show that Hippo pathway alterations are a feature of sRCC, and ena

48 talk of ARF/beta-catenin dysregulated YAP in Hippo pathway and a new approach to stimulate ARF-mediat

49 ining adaptor Amot, which regulates both the Hippo pathway and actin dynamics.

50 nd TP53BP2, leading to the inhibition of the Hippo pathway and activation of YAP1, which gave rise to

51 cells leads to spontaneous activation of the Hippo pathway and alleviates the need for SAV1 in Hippo

52 he unknown interaction between the canonical Hippo pathway and cell tension.

53 in cancer, development and regeneration, via Hippo pathway and cytoskeleton regulation.

54 e and is associated with inactivation of the Hippo pathway and increase in yes-associated protein (Ya

55 irways maintain quiescence by activating the Hippo pathway and inhibiting Fgf10 expression in airway

56 The Hippo pathway and its downstream effectors YAP and TAZ (

57 Recently, the Hippo pathway and its transcriptional co-activator Yes-a

58 e data link transcriptional effectors of the Hippo pathway and of mechanotransduction to myelin forma

59 have shown evidence of crosstalk between the Hippo pathway and other key signaling pathways, such as

60 dies have highlighted a central role for the Hippo pathway and other signaling networks in regulating

61 We discuss cancer-related functions of the Hippo pathway and potential explanations for the cancer-

62 crucial intracellular cue that regulates the Hippo pathway and that triggering SOCE could be a strate

63 Ezrin has a direct role in the regulation of Hippo pathway and Yap.

64 Dysregulated Hippo pathway and YAP/TAZ-TEAD activity is associated wi

65 AD interaction at the heart of the oncogenic Hippo pathway, and possessing the potency and stability

66 New and exciting studies of the Hippo pathway are anticipated that will significantly im

67 by a hierarchical model in which elements of Hippo pathway are under the control of focal adhesions (

68 , the major transcriptional mediators of the Hippo pathway, are critical for expression of caveolae c

69 iption factors, which lie at the core of the Hippo pathway, are essential for regulation of organ gro

70 Recent studies have expanded the Hippo pathway as a complex signaling network with >30 co

71 e of sRCC, and enable the exploration of the Hippo pathway as a novel potential therapeutic target.

72 However, it is not well understood how the Hippo pathway becomes dysregulated because few mutations

73 dergo mitotic catastrophe, modulated via the Hippo pathway but independent of Wnt-beta-catenin.

74 es the WW domain binding specificity for the Hippo pathway, but also reveals STXBP4 as a player in ac

75 inhibition does not depend on the canonical Hippo pathway, but relies on enhanced degradation mediat

76 is an important model to understand how the Hippo pathway can be inhibited in cancer, and provide ap

77 activity between the mechanosensing and the Hippo pathways can be explained by the interaction of LI

78 and bantam, that are classic targets of the Hippo pathway coactivator Yorkie.

79 Here we show that deletion of the Hippo pathway component Salvador (Salv) in mouse hearts

80 ession of yes associated protein 1 (YAP1), a Hippo pathway component that itself was associated with

81 he paralogous gene history for the mammalian Hippo pathway components and characterized their cancer-

82 verview of the functional importance of many Hippo pathway components and demonstrate NF2 and RHOA as

83 We introduce the Hippo pathway components and major upstream signals that

84 lished the WW domain binding specificity for Hippo pathway components and uncovered a unique amino ac

85 an cancer has remained enigmatic inasmuch as Hippo pathway components are rarely mutated in tumors.

86 Hippo pathway components are structurally and functional

87 s dysregulated because few mutations in core Hippo pathway components have been identified.

88 ne the activity of YAP and the expression of Hippo pathway components in tumor and non-neoplastic liv

89 we show that PCBP2 forms a complex with the Hippo pathway components Salvador (Sav1), Mst1, Mst2, an

90 aSFs cluster Hippo pathway components, thereby scaling Hippo signalin

91 To provide an overview of important Hippo pathway components, we created knockout cell lines

92 The core of the Hippo pathway consists of a kinase cascade, transcriptio

93 These core components of the Hippo pathway control transcriptional programs involved

94 Here we report that the Hippo pathway controls liver cell lineage specification

95 The Hippo pathway controls organ growth and is implicated in

96 The Hippo pathway controls organ size and tissue homeostasis

97 Here we report that the Hippo pathway controls the proliferation and specificati

98 The Hippo pathway controls tissue growth and homeostasis thr

99 PRKCQ, JUN, and the Hippo pathway coordinately regulate GIST cyclin D1 expre

100 ur extracts revealed specific alterations in Hippo pathway core components, as a function of DDR and

101 ate YAP, an effector in the mechanosensitive Hippo pathway, correlates with regenerative capacity in

102 is reduced tension modulates a biomechanical Hippo pathway, decreasing recruitment of Ajuba LIM prote

103 (H)2 and T(H)17) effector T cells by Wnt and Hippo pathway-dependent mechanisms.

104 Greater understanding of Hippo pathway deregulation in cancers will be essential

105 Hippo pathway deregulation is also enriched in squamous

106 In the liver, Hippo pathway deregulation promotes hyperplasia and hepa

107 The Hippo pathway directs cell differentiation during organo

108 Here, we provide an updated review of the Hippo pathway; discuss its roles in development, homeost

109 Here, we investigate the function of the Hippo pathway during the development of cartilage, which

110 r during bile duct development by binding to Hippo pathway effector proteins YAP1, TAZ and TEAD4 and

111 dermal growth factor receptor (EGFR) and the Hippo pathway effector TAZ in human cancer cells.

112 the pro-survival signaling of the downstream Hippo pathway effector YAP (Yes-associated protein) in D

113 Here, we report that the Hippo pathway effector Yap promotes the diploid-polyploi

114 e geometry (i.e. shape and position) and the Hippo pathway effector YAP remains unknown.

115 dystroglycan 1 (Dag1) directly binds to the Hippo pathway effector Yap to inhibit cardiomyocyte prol

116 Here, we show that an active version of the Hippo pathway effector YAP, termed YAP5SA, partially rep

117 roteins, which are potent inhibitors for the Hippo pathway effector YAP.

118 t genes was cooperatively regulated with the Hippo pathway effector Yap.

119 enerative/tumorigenic program, driven by the Hippo pathway effector Yap.

120 RASSF1A degradation is necessary to permit Hippo pathway effector YAP1 association with SMADs and s

121 transformation through the activation of the Hippo pathway effector YAP1.

122 Here, we report that the levels of the Hippo pathway effector Yes-associated protein (Yap) are

123 ed completely novel roles for Merlin and the Hippo pathway effector Yes-associated protein (YAP) in t

124 Hedgehog (Hh) signaling induces the Hippo pathway effector Yorkie (Yki) to promote prolifera

125 nnectivity between the NF-kappaB pathway and Hippo pathway effectors at the transcriptional level, th

126 Together, these studies suggest that the Hippo pathway effectors Yap and Taz are important transc

127 cascade that culminates in activation of the Hippo pathway effectors YAP and TAZ is frequently altere

128 tor of cyclin D1 expression, whereas JUN and Hippo pathway effectors YAP and TAZ were positive regula

129 Here, we show that the Hippo pathway effectors YAP and TAZ work as crucial sign

130 eficient in epicardial YAP and TAZ, two core Hippo pathway effectors, developed profound post-MI peri

131 eptor tyrosine kinase c-Src and recruits the Hippo pathway effectors, Yap (yes-associated protein) an

132 We found that the Wnt-FoxO-Hippo pathway (from E10.5 to E11.5), tissue remodeling (

133 sphorylation, revealing a connection between Hippo pathway function and the DGC.

134 en immediate early transcription of AP-1 and Hippo pathway function.

135 Large-scale pan-cancer analyses of core Hippo pathway genes reveal that the pathway is mutated a

136 We identified three Hippo pathway genes, LATS2, TAOK1, and NF2, as key deter

137 e cancer-restricted mutation profile of core Hippo pathway genes.

138 Thus, the Hippo pathway has a physiological function as an integra

139 Initially discovered in Drosophila, the Hippo pathway has been implicated as an evolutionarily c

140 The major functions of the Hippo pathway have been defined to restrict tissue growt

141 More diverse functions of the Hippo pathway have been recognized, including developmen

142 S2 kinases, core components of the mammalian Hippo pathway, have been shown to exert tumor suppressiv

143 tes cell proliferation via regulation of the Hippo pathway, highlighting the potential of protein ter

144 acetyltransferase is a negative regulator of Hippo pathway (HP) gene expression.

145 Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor imm

146 h advances around the core components of the Hippo pathway in cancer.

147 is mutant could rescue signaling through the Hippo pathway in cells lacking multiple MST kinases.

148 nscriptional effectors and regulators of the Hippo pathway in establishing LR asymmetry.

149 s not noticeably impair the functions of the Hippo pathway in eye growth regulation.

150 bes how a palmitoyltransferase regulates the Hippo pathway in flies.

151 eptor type 14) which, in turn, regulated the Hippo pathway in GBM.

152 involvement of SCD1 in the regulation of the Hippo pathway in lung cancer, and point to fatty acids m

153 erview on the regulation and function of the Hippo pathway in mammalian early development.

154 The core of the Hippo pathway in mammals consists of a kinase cascade, M

155 Our data define the central role of Hippo pathway in mediating resistance to BETi and provid

156 Our observations uncover a key role of the Hippo pathway in modulating tumor immunogenicity and dem

157 e describe a previously unknown role for the Hippo pathway in myelination.

158 on, providing insights into functions of the Hippo pathway in normal and abnormal tissue growth.

159 lomerulus, including acute activation of the Hippo pathway in podocytes after nephrotoxic immune inju

160 between nephrin signaling and the canonical Hippo pathway in podocytes, which may facilitate the con

161 In this study, we traced the Hippo pathway in premetazoan species, characterized the

162 The activity state of the Hippo pathway in R8 cells is determined by the expressio

163 IKV replication, indicating a direct role of Hippo pathway in regulating ZIKV infection.

164 t in lipid binding is unable to activate the Hippo pathway in response to osmotic stress, as measured

165 critical for its function in activating the Hippo pathway in response to osmotic stress.

166 ere, we discovered an unexpected role of the Hippo pathway in suppressing anti-tumor immunity.

167 to and Sasaki (2019) explore the role of the Hippo pathway in the establishment of naive pluripotency

168 We also discuss the roles of Hippo pathway in tissue specification and organ developm

169 s exhibit loss of function in modulating the Hippo pathway, inducing CIP, as well as attenuated suppr

170 Our study indicates that Hippo pathway inhibition is required for the increased m

171 evidence that IKBKE regulates AR levels via Hippo pathway inhibition to reduce c-MYC levels at cis-r

172 Extensive studies have shown that the Hippo pathway inhibits cell proliferation, and survival

173 the main transcriptional coactivator of the Hippo pathway, integrates multiple inputs from different

174 the Yes-associated protein 1, is part of the Hippo pathway involved in development, growth, repair an

175 nscriptional co-activators downstream of the Hippo pathway involved in the regulation of organ size,

176 In BRCA1-deficient cells Hippo pathway is "turned On." Phosphorylation of YAP1 is

177 The Hippo pathway is a central regulator of organ size and a

178 The Hippo pathway is a master regulator of tissue homeostasi

179 The Hippo pathway is a well-conserved signaling cascade that

180 Hippo pathway is activated in major cellular components

181 The Hippo pathway is an evolutionarily conserved kinase casc

182 The Hippo pathway is an evolutionarily conserved signaling p

183 The Hippo pathway is an evolutionarily conserved signalling

184 The Hippo pathway is an important regulator of cell growth,

185 Though functional inactivation of the Hippo pathway is common in tumors, mutations in core pat

186 Here we show that the Hippo pathway is critical for this decision.

187 The Hippo pathway is crucial for not only normal growth and

188 The Hippo pathway is crucial in organ size control and tissu

189 Since the Hippo pathway is deregulated in various cancers, designi

190 Here, we found that the Hippo pathway is directly regulated by the hexosamine bi

191 The Hippo pathway is emerging as a key evolutionarily conser

192 The Hippo pathway is important for regulating tissue homeost

193 The Hippo pathway is involved in regulating contact inhibiti

194 F2 mediates upstream signals to regulate the Hippo pathway is not clear.

195 activated in human malignancies in which the Hippo pathway is still active.

196 The Hippo pathway is tightly regulated by both intrinsic and

197 aling networks such as the Ras/rac, Akt, and Hippo pathways is well-documented, in mammals as well as

198 ng pathway, also known as the Salvador-Warts-Hippo pathway, is a regulator of organ size.

199 o-factor that is negatively regulated by the Hippo pathway, is crucial for the development and size c

200 ptional regulator Yap, a key effector of the Hippo pathway, is required for the proper patterning and

201 demonstrate that YAP activity decreases and Hippo pathway kinase activities increase upon differenti

202 h and invasiveness through regulation of the Hippo pathway kinase large tumor suppressor 2 (LATS2) an

203 The Hippo pathway kinase Lats1/2 (large tumor suppressor hom

204 3K9 (H3K9me2) silenced the expression of the Hippo pathway kinase LATS2, and this effect led to subse

205 Mad and dSmad2 cooperate to modulate the Hippo pathway kinase Warts and the growth regulator Melt

206 ing recruitment of Ajuba LIM protein and the Hippo pathway kinase Warts, and decreasing the activity

207 We examined the function of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1

208 mor models (B16, SCC7, and 4T1), loss of the Hippo pathway kinases LATS1/2 (large tumor suppressor 1

209 Conditional deletion of Hippo pathway kinases, Lats1 and Lats2, in uninjured CFs

210 Furthermore, dysregulation of the Hippo pathway leads to aberrant cell growth and neoplasi

211 The hippo pathway leads to phosphorylation of the transcript

212 ed on these data we propose that NF2 and the Hippo pathway locally repress YAP/TAZ activity in the UB

213 Drosophila Hippo pathway maintains NSC quiescence, but its regulati

214 The Hippo pathway maintains tissue homeostasis by negatively

215 In the adult liver, the Hippo pathway mammalian STE20-like protein kinases 1 and

216 findings show that both inactivation of the Hippo pathway (nuclear Yap) or ablation of Yap result in

217 to Merlin degradation, downregulation of the Hippo pathway, nuclear Yap translocation, and expression

218 n initiation network (SIN), analogous to the Hippo pathway of multicellular organisms, is a signaling

219 rovided novel evolutionary insights into the Hippo pathway organization and oncogenic alteration.

220 /Taz stabilization in the nucleus to sustain Hippo pathway outputs.

221 ession of PAR1, an upstream regulator of the Hippo pathway; PAR1 promotes invasion, migration, and CS

222 nd LATS2 kinases, the core components of the Hippo pathway, phosphorylate S606 of Raptor, an essentia

223 The Hippo pathway plays a critical role in development, tiss

224 The Hippo pathway plays an important role in developmental b

225 The Hippo pathway plays critical roles in cell growth, diffe

226 The Hippo pathway plays essential roles in organ size contro

227 The Hippo pathway plays major roles in development, regenera

228 fusible chemical components can regulate the Hippo pathway primarily through receptors embedded in th

229 inases (LATS) 1 and 2, which are part of the Hippo pathway, promotes the luminal phenotype and increa

230 onical pathway involving gp130, Src, and the Hippo pathway protein YAP.

231 tein-protein interaction regions between the Hippo pathway protein Yes-associated protein 2 (YAP2) an

232 ivo and suggest that Ctp may interact with a Hippo pathway protein(s) to exert inverse transcriptiona

233 The Hippo pathway regulates cell proliferation and organ siz

234 The Hippo pathway regulates myriad biological processes in d

235 The Hippo pathway regulates organ size, regeneration, and ce

236 The Hippo pathway regulates the self-renewal and differentia

237 YAP/TEAD are nuclear effectors of the Hippo pathway, regulating organ size and tumorigenesis l

238 ferent YAP1 fusions is resistant to negative Hippo pathway regulation due to constitutive nuclear loc

239 and Kibra, identify a subcellular domain for Hippo pathway regulation, and demonstrate differential a

240 r study identifies an unanticipated layer of Hippo pathway regulation, defines a novel mechanism by w

241 itide dynamics, specifically PI(4,5)P(2), in Hippo pathway regulation.

242 layer in actin cytoskeleton tension-mediated Hippo pathway regulation.

243 ne amplification and genetic inactivation of Hippo pathway regulators.

244 reen in human cancer cells to identify novel Hippo pathway regulators.

245 ivation via a previously unappreciated FSTL5-Hippo pathway regulatory axis.

246 The Hippo pathway remains a central focus in both basic and

247 their stem cell state by downregulating the Hippo pathway (resulting in increased nuclear Yap), whic

248 nterference with the YAP-TEAD complex of the HIPPO pathway, resulting in growth inhibition of several

249 deficient tumors exhibit deregulation of the Hippo pathway.See related commentary by Brekken, p.

250 Here, we investigated the functions of the Hippo pathway serine/threonine-protein kinases Lats1 and

251 -mediated transformation and maintain active hippo pathway signaling compared to wild-type cells or c

252 Hippo pathway signaling limits cell growth and prolifera

253 ML2 fusions were identified as activators of Hippo-pathway signaling in multiple cancer types.

254 highlights the key findings from studies of Hippo pathway signalling across biological processes and

255 olog named Yorkie (Yki) that is regulated by Hippo pathway signalling in response to epithelial polar

256 ion of AGR2 also has opposing effects on the Hippo pathway, spheroid formation, and response to chemo

257 of YAP as well as chemical inhibitors of the Hippo pathway such as S1P recover the ER instability and

258 nfirms a reliance on elements of the 20E and Hippo pathways, such as Yki and the Yki-Tai target dilp8

259 ses to restrain Rho GTPase activity, support Hippo pathway suppressor functions, and restrain prostat

260 onnection between cell cycle progression and Hippo pathway target expression, providing insights into

261 wing imaginal epithelium leads to increased Hippo pathway target gene expression but does not affect

262 kidneys associated with the upregulation of Hippo pathway target genes and marker genes of TGF-beta

263 he MST-LATS kinase cascade is central to the Hippo pathway that controls tissue homeostasis, developm

264 Yap and Taz are effectors of the Hippo pathway that integrate chemical and mechanical sig

265 verging on the transcriptional output of the Hippo pathway that may be exploited for modulating the Y

266 asts upon tissue damage or activation of the Hippo pathway that promotes regeneration of intestinal e

267 zation of YAP1 protein and turning "off" the Hippo pathway through ubiquitination of NF2.

268 de cells rely on apicobasal polarity and the Hippo pathway to choose their fate.

269 binding motif (TAZ) are key effectors of the Hippo pathway to control cell growth and organ size, of

270 Therefore, these results link the Hippo pathway to EGFR-mediated renal epithelial injury i

271 a role for transcriptional regulators of the Hippo pathway to facilitate protein scavenging and suppo

272 ot only traced the conserved function of the Hippo pathway to its unicellular ancestor components, bu

273 n effector that transduces the output of the Hippo pathway to transcriptional modulation.

274 ein (YAP), one of the major effectors of the Hippo pathway together with its related protein WW-domai

275 Recent studies have implicated the Hippo pathway transcriptional coactivator protein YAP1 a

276 Hippo pathway transcriptional coactivators TAZ and YAP a

277 The Hippo pathway transcriptional coactivators YAP/TAZ were

278 We show that the Hippo pathway transcriptional coactivators Yap1 and Wwtr

279 We examined the role of the Hippo pathway transcriptional coactivators Yes-associate

280 RASSF1A reduced nuclear accumulation of the Hippo pathway transcriptional cofactor Yes-associated pr

281 Our results reveal how the Hippo pathway transcriptional program, localized to two

282 erin, triggering nuclear localization of the Hippo pathway transcriptional regulator Yap1 and endocar

283 Loss of Hippo pathway tumor suppressors or activation of Yorkie

284 iquitin ligases that negatively regulate the Hippo pathway via ubiquitination, yet few deubiquitinati

285 The Hippo pathway was deregulated in BAP1-deficient pancreat

286 The Hippo pathway was initially discovered in Drosophila mel

287 tinctive dependency on YAP1 and WWTR1 of the Hippo pathway, where the lost-of-fitness effect of one p

288 host cell signaling pathways, including the Hippo pathway which controls cell proliferation and diff

289 a downstream nuclear transcription factor of Hippo pathway which plays an essential role in developme

290 f YAP1 (a transcriptional coactivator in the Hippo pathway), which in turn promoted autophagy, wherea

291 echanism by which cell density activates the Hippo pathway, which in turn inactivates YAP, leading to

292 The Hippo pathway, which plays a critical role in organ size

293 ne central cellular signaling pathway is the Hippo pathway, which regulates homeostasis and plays chi

294 ciated protein (YAP), the main target of the Hippo pathway, which results in decreased expression of

295 lar mechanisms by which signals regulate the Hippo pathway with an emphasis on mechanotransduction an

296 Mechanistically, the core component of Hippo pathway (YAP) is O-GlcNAcylated by O-GlcNAc transf

297 nctions for the two nuclear effectors of the Hippo pathway, Yap and Taz, during lung development.

298 inase, is directly involved in regulation of Hippo pathway, Yap levels, and growth of normal and neop

299 ng adenocarcinoma, that the effectors of the Hippo pathway, Yes-associated protein (YAP) and transcri

300 that the transcriptional coactivator of the Hippo pathway, Yorkie (YAP/TAZ in vertebrates), plays di